A new study published in the Journal of European Academy of Dermatology and Venerology showed that compared to patients on ...

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the ...

Biosimilar denosumab of Alkem (Denuril) showed comparable efficacy, safety, pharmacokinetics, pharmacodynamics, and ...

Rodolfo Hrosz has chosen to step down from his position as Managing Director of the company, effective April 30. He will be ...

Denosumab works by specifically targeting the RANK ligand (RANKL), a critical protein in the lifecycle of osteoclasts, the ...

As per the company, the drug functions by blocking a protein called RANKL, which is responsible for breaking down bone tissue ...

The company's subsidiary, CuraTeQ Biologics, has successfully completed the Phase 1 pharmacokinetic (PK) and pharmacodynamic ...

Infosys, BHEL, Sun Pharma, NBCC (India), Bharti Hexacom, Eternal, Aurobindo Pharma and TARC will be in the spotlight on ...

As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for ...

Celltrion gains Australian approval for three biosimilars in ophthalmology and bone disease Celltrion secures TGA endorsement ...

Accord received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for ...